Atherosclerosis最新文献

{"title":"Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial","authors":"Jie Lin ,&nbsp;Yuan Ji ,&nbsp;Gaopin Wang ,&nbsp;Xueping Ma ,&nbsp;Zhuhua Yao ,&nbsp;Xuebin Han ,&nbsp;Jie Chen ,&nbsp;Jiyan Chen ,&nbsp;Wei Huang ,&nbsp;Guangma Xu ,&nbsp;Daoquan Peng ,&nbsp;Peishi Yan ,&nbsp;Ping Qiao ,&nbsp;Yongming He ,&nbsp;Yida Tang ,&nbsp;Minghui Wang ,&nbsp;Mengqi Zhang ,&nbsp;Jianjun Yu ,&nbsp;Yu Hao ,&nbsp;Changsheng Ma","doi":"10.1016/j.atherosclerosis.2025.119120","DOIUrl":"10.1016/j.atherosclerosis.2025.119120","url":null,"abstract":"<div><h3>Background and aims</h3><div>Heterozygous familial hypercholesterolemia (HeFH) is a prevalent autosomal dominant disorder of lipid metabolism but severely underdiagnosed and undertreated in China. This phase 3 trial aims to evaluate the efficacy and safety of ongericimab, a novel monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), in Chinese patients with HeFH.</div></div><div><h3>Methods</h3><div>Patients who have been diagnosed with definite HeFH according to Dutch Lipid Clinical Network criteria and receiving stable and optimized lipid-lowering therapy were enrolled. A total of 135 patients were randomly assigned in a 2:1:2:1 ratio to receive either ongericimab 150 mg or matching placebo every 2 weeks (Q2W), or ongericimab 450 mg or matching placebo every 4 weeks (Q4W) for 24 weeks. Patients were stratified according to the use of high-intensity statins. The primary endpoint was the percentage change in LDL-C from baseline to week 24.</div></div><div><h3>Results</h3><div>Our findings demonstrated that treatment with ongericimab resulted in a significant reduction in LDL-C at week 24. The least-squares mean difference was −69.4 % (95 % confidence interval [CI]: −80.9 %, −57.9 %; <em>p</em> &lt; 0.0001) for the ongericimab 150 mg Q2W group, and −80.6 % (95 % CI: −92.1 %, −69.1 %; <em>p</em> &lt; 0.0001) for ongericimab 450 mg Q4W group compared to respective matching placebo groups. Meanwhile, ongericimab also favorably altered other lipid parameters. A similar incidence of adverse events was observed in the ongericimab and placebo groups.</div></div><div><h3>Conclusions</h3><div>Ongericimab administered at either 150 mg Q2W or 450 mg Q4W for 24 weeks, significantly reduced LDL-C levels and was well-tolerated in Chinese patients with HeFH.</div></div><div><h3>Clinical trial registration</h3><div><span><span>http://www.clinicaltrials.gov</span><svg><path></path></svg></span>; Unique Identifier: NCT05325203.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"403 ","pages":"Article 119120"},"PeriodicalIF":4.9,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA","authors":"Eliot A. Brinton ,&nbsp;Robert H. Eckel ,&nbsp;Daniel Gaudet ,&nbsp;Christie M. Ballantyne ,&nbsp;Brenda F. Baker ,&nbsp;Henry N. Ginsberg ,&nbsp;Joseph L. Witztum","doi":"10.1016/j.atherosclerosis.2025.119114","DOIUrl":"10.1016/j.atherosclerosis.2025.119114","url":null,"abstract":"<div><div>Familial chylomicronemia syndrome (FCS) is a rare, recessive monogenic disorder characterized by severely elevated plasma triglyceride (TG) levels due to absent or markedly impaired lipoprotein lipase activity, leading to a greatly increased risk of acute pancreatitis. Naturally occurring very low levels of apoC-III are associated with low TG levels; thus, apoC-III is a target for TG lowering, and therapies have been developed to reduce apoC-III. Strategies to inhibit hepatic apoC-III synthesis include antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). In the last decade, technologies have been developed to enhance hepatic delivery of these potential therapeutic agents by conjugation of the ligand triantennary N-acetyl galactosamine to ASO and siRNA for receptor-mediated uptake by hepatocytes, where apoC-III is predominantly expressed. Enhanced delivery of these pharmacological agents to the target tissue has been found to support lower and/or less frequent dosing with consequent lower total systemic exposure. One antisense agent, the ASO olezarsen, is now approved by the US Food and Drug Administration (FDA) as an adjunct to diet to lower triglycerides in adults with FCS, and the other, the siRNA plozasiran, is in late-stage clinical development. Both agents have shown effectiveness in reducing both apoC-III and TG levels across several study populations. Reduced TG, lower rates of acute pancreatitis events, and similar proportions of adverse events in placebo and treated patients were recently demonstrated in placebo-controlled phase 3 trials of patients with FCS treated with olezarsen in Balance and with plozasiran in PALISADE. This review discusses causes and consequences of FCS and the rationale and progress made in developing <em>APOC3</em> RNA–targeted therapeutics for the treatment of FCS.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"403 ","pages":"Article 119114"},"PeriodicalIF":4.9,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caveolin-1-mediated LDL transcytosis across endothelial cells in atherosclerosis","authors":"Yifei Zhang ,&nbsp;Xiong Jia ,&nbsp;Yayu Wang ,&nbsp;Qijun Zheng","doi":"10.1016/j.atherosclerosis.2025.119113","DOIUrl":"10.1016/j.atherosclerosis.2025.119113","url":null,"abstract":"<div><div>Atherosclerosis is widely recognized as a chronic inflammatory disease of the arterial wall characterized by the progressive accumulation of lipids, inflammatory cells, and fibrous material in the subendothelial space of large arteries. The occurrence and pathogenesis of atherosclerosis are intricately linked to the deposition of low-density lipoprotein (LDL) in the arterial wall. LDL must cross the intact endothelium to reach the subendothelial space, with caveolin-1 assuming a crucial role in this process. Caveolin-1 is a 21–24 kDa membrane protein located in caveolae and highly expressed in endothelial cells. Previous investigations have demonstrated the pivotal role of caveolin-1 in fostering atherosclerosis through its modulation of membrane trafficking, cholesterol metabolism, and cellular signaling. However, how caveolin-1 regulates LDL transcytosis across endothelial cells in atherosclerosis remains unclear. We provide a comprehensive overview of recent research on the interplay between caveolin-1 and atherosclerosis, with a specific focus on elucidating the role of caveolin-1 in mediating LDL transcytosis across endothelial cells. This review furnishes theoretical foundations supporting the pivotal role of caveolin-1 in both the inception and progression of atherosclerosis. It underscores the prospective viability of caveolin-1 as a new therapeutic target for atherosclerosis and introduces novel perspectives for treatment strategies in the early stages of atherosclerosis.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"402 ","pages":"Article 119113"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143354545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization","authors":"Dilin Xu ,&nbsp;Jin Lu ,&nbsp;Yanfang Yang ,&nbsp;Wangxing Hu ,&nbsp;Jinyong Chen ,&nbsp;Junhui Xue ,&nbsp;Shuangshuang Yang ,&nbsp;Naifang Cao ,&nbsp;Haochang Hu ,&nbsp;Ningjing Qian ,&nbsp;Dao Zhou ,&nbsp;Hanyi Dai ,&nbsp;Jian'an Wang ,&nbsp;Xianbao Liu","doi":"10.1016/j.atherosclerosis.2025.119110","DOIUrl":"10.1016/j.atherosclerosis.2025.119110","url":null,"abstract":"<div><h3>Background and aims</h3><div>Calcific aortic valve disease (CAVD) is characterized by progressive leaflet thickening and calcification, with no available pharmacological treatments. Plasma proteins play a pivotal role in disease regulation. This study aimed to uncover novel therapeutic targets for CAVD using Mendelian randomization (MR) integrated with transcriptomic analysis.</div></div><div><h3>Methods</h3><div>Protein quantitative trait loci (pQTL) from the deCODE and UK Biobank Pharma Proteomics Project (UKB-PPP) plasma protein databases were used as exposure data. The FinnGen cohort (9870 cases, 402,311 controls) served as the discovery set, while the TARGET cohort (13,765 cases, 640,102 controls) provided validation. MR and summary data-based Mendelian randomization (SMR) were employed to screen for potential causal targets of CAVD. Colocalization analysis was conducted to assess whether CAVD and target proteins shared common causal SNPs. Additional analyses included trancriptomic profiling at multiple RNA levels. Protein-level validation was conducted via Western blot and immunostaining.</div></div><div><h3>Results</h3><div>Six proteins (ANGPTL4, PCSK9, ITGAV, CTSB, GNPTG, and FURIN) with strong genetic colocalization were identified by MR and SMR analysis. Among these, cellular trancriptomic analysis revealed ANGPTL4 and ITGAV with significantly greater expression in osteogenic group, which was further validated in calcified aortic valves and osteogenic valvular interstitial cells in protein level.</div></div><div><h3>Conclusions</h3><div>This study identified six causal proteins with strong genetic colocalization for CAVD, with ANGPTL4 and ITGAV emerging as the most promising targets for further investigation.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"402 ","pages":"Article 119110"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143354547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet Content from Acute Myocardial Infarction Patients: Elevated Levels of IL-6 and IL-8 and their impact on Endothelial Nitric Oxide Production","authors":"Diego Arauna ,&nbsp;Emerson Chandia ,&nbsp;Estefanía Nova-Lamperti ,&nbsp;Claudia Radojkovic ,&nbsp;Eduardo Fuentes ,&nbsp;Iván Palomo ,&nbsp;Enrique Guzmán-Gutiérrez ,&nbsp;Rodrigo Moore-Carrasco ,&nbsp;Claudio Aguayo","doi":"10.1016/j.atherosclerosis.2025.119119","DOIUrl":"10.1016/j.atherosclerosis.2025.119119","url":null,"abstract":"<div><h3>Background and aims</h3><div>Platelets and inflammation play crucial roles in the atherothrombotic process of acute myocardial infarction (AMI), particularly in ischemia/reperfusion injury. This study aims to characterize the pro-inflammatory content of the platelet secretome in AMI patients, assess its effect on nitric oxide (NO) production, and correlate these findings with clinical parameters.</div></div><div><h3>Methods</h3><div>Blood samples from 20 AMI patients and 20 controls were analyzed. Platelets were isolated and stimulated with thrombin, and their secretomes were collected. Endothelial cells were exposed to these secretomes, and NO production was measured. Our results demonstrate a significant reduction in NO production in endothelial cells exposed to the AMI platelet secretome (p &lt; 0.05), suggesting acute endothelial dysfunction.</div></div><div><h3>Results</h3><div>Elevated levels of interleukin-6 (IL-6) (p = 0.0323) and interleukin-8 (IL-8) (p = 0.0197) were identified in the secretome of AMI patients, correlating with clinical markers of myocardial injury. Specifically, IL-6 positively correlated with CK-MB levels (p = 0.04, Pearson r = 0.53), while IL-8 levels inversely correlated with NO production (p = 0.0141, Pearson r = −0.5652).</div></div><div><h3>Conclusions</h3><div>These findings underscore the critical role of platelet-derived IL-6 and IL-8 in endothelial dysfunction and myocardial injury in AMI patients. Future studies should explore the interactions between these cytokines in endothelial cells to further elucidate their roles in AMI pathology.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"403 ","pages":"Article 119119"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of calcification severity adjacent to calcified nodule: Its association with first and recurrent risks of target lesion revascularization after percutaneous coronary intervention","authors":"Naoya Yabumoto ,&nbsp;Masashi Fujino ,&nbsp;Hiroki Sugane ,&nbsp;Hayato Hosoda ,&nbsp;Satoshi Kitahara ,&nbsp;Yusuke Fujino ,&nbsp;Kenichiro Sawada ,&nbsp;Kota Murai ,&nbsp;Takamasa Iwai ,&nbsp;Satoshi Honda ,&nbsp;Hideo Matama ,&nbsp;Kazuhiro Nakao ,&nbsp;Shuichi Yoneda ,&nbsp;Kensuke Takagi ,&nbsp;Fumiyuki Otsuka ,&nbsp;Yasuhide Asaumi ,&nbsp;Eri Kiyoshige ,&nbsp;Soshiro Ogata ,&nbsp;Kunihiro Nishimura ,&nbsp;Kazuya Kawai ,&nbsp;Yu Kataoka","doi":"10.1016/j.atherosclerosis.2025.119116","DOIUrl":"10.1016/j.atherosclerosis.2025.119116","url":null,"abstract":"<div><h3>Background and aims</h3><div>Calcified nodule (CN) is a plaque phenotype characterized by protruding calcification, associated with repeat revascularization after percutaneous coronary intervention (PCI). The severity of calcification increases the risk of future target lesion revascularization (TLR). This study was conducted to determine whether calcification severity in the adjacent zone is associated with TLR.</div></div><div><h3>Methods</h3><div>We analyzed 204 patients who received PCI for de-novo CN using intravascular ultrasound (IVUS). The calcium volume index (CVI) was calculated for each 1-mm cross-sectional frame in both the CN and adjacent zones.</div></div><div><h3>Results</h3><div>TLR occurred in 63 patients (30.9 %) during a median follow-up period of 2.8 years (interquartile range, 2.4–3.2). CVIs in both the CN and adjacent zones, along with minimum lumen area (MLA) after PCI, were significant predictors of TLR. The ROC curve-derived values for the CVIs in the CN and adjacent zones (10.52 and 5.33, respectively) and the MLA after PCI (6.65 mm²) were associated with higher TLR incidence. Among those requiring TLR, 27.0 % experienced multiple TLRs, with higher CVIs associated with recurrence. In a multi-state model, CVIs in both the CN and adjacent zones were significantly associated with the first TLR (no TLR as reference) and the second TLR (first TLR as reference). The CVI in the adjacent zone showed a higher hazard ratio for the second TLR (1.31; 95 % confidence interval [CI]: 1.16–1.48) compared to the first TLR (1.12; 95 % CI: 1.07–1.17).</div></div><div><h3>Conclusions</h3><div>Our findings highlight the importance of not only the calcification severity in the CN zone, but also in the adjacent zones, for TLR.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"402 ","pages":"Article 119116"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143142557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron biomarkers predict peripheral artery disease in females","authors":"Anand Ruban Agarvas ,&nbsp;Stefan Kopf ,&nbsp;Tiago J.S. Lopes ,&nbsp;Janice L. Atkins ,&nbsp;Paul Thalmann ,&nbsp;José Manuel Fernández-Real ,&nbsp;Peter Nawroth ,&nbsp;Martina U. Muckenthaler","doi":"10.1016/j.atherosclerosis.2025.119111","DOIUrl":"10.1016/j.atherosclerosis.2025.119111","url":null,"abstract":"<div><h3>Background and aim</h3><div>Iron overload has been proposed as a risk factor for atherosclerosis, but the available data are controversial. Here, we investigated whether iron status shows sex-specific associations with peripheral arterial disease (PAD).</div></div><div><h3>Methods</h3><div>Using two different analytical approaches (machine-learning and logistic regression), we studied the association between blood iron biomarkers and PAD in 368 individuals from the Heidelberg Study on Diabetes and Complications (HEIST-DiC) and in 5101 individuals from the National Health and Nutrition Examination Survey (NHANES 1999–2004). Additionally, by analysing data from the UK Biobank, we investigated the odds of PAD in individuals with hemochromatosis genotypes (n = 448,575).</div></div><div><h3>Results</h3><div>We found that iron biomarkers were among the top predictors of PAD in the machine-learning classification in both cohorts. In the HEIST-DiC cohort, ferritin, iron, and transferrin were ranked among the top predictive markers, while in the NHANES cohort, ferritin, total iron binding capacity (TIBC), transferrin saturation (TSAT) and iron showed high predictive power. In the regression analysis, ferritin showed a positive interaction among females in the HEIST-DiC (OR 2.68, 95% CI 0.94–7.61, P = 0.057) and NHANES cohorts (OR 1.76, 95% CI 1.16–2.67, P = 0.008). The multivariable regression analysis of the NHANES cohort detected a nonlinear relationship between ferritin and PAD, in that, certain ferritin ranges (48–97 ng/mL: OR 14.59, 95% CI 1.6–135.93, P = 0.019; 98–169 ng/mL: OR 171.07, 95% CI 1.27–23404, P = 0.039) in females were positively associated with PAD. Nevertheless, we did not detect significant associations between hemochromatosis genotypes and PAD in the UK Biobank.</div></div><div><h3>Conclusion</h3><div>Taken together, our data show that iron biomarkers, importantly, elevated ferritin within physiological limits are associated with clinically apparent PAD in females. These findings add to the body of evidence suggesting sex differences in PAD and highlight a possible role of iron (directly or indirectly) in this relationship.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"402 ","pages":"Article 119111"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143350003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in heart health – Insights from Sweden","authors":"Joany Mariño Coronado ,&nbsp;Anna Lebedeva ,&nbsp;Martin Bahls","doi":"10.1016/j.atherosclerosis.2025.119104","DOIUrl":"10.1016/j.atherosclerosis.2025.119104","url":null,"abstract":"","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"402 ","pages":"Article 119104"},"PeriodicalIF":4.9,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143143086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sagittal abdominal diameter: A novel and potentially superior indicator than waist circumference for diagnosis of central obesity, based on evidence from multiple data sources","authors":"Zhuoqing Hu ,&nbsp;Rutao Liang ,&nbsp;Yimei Chen ,&nbsp;Wen Shi ,&nbsp;Liankun Zeng ,&nbsp;Chao Li ,&nbsp;Guanni Li ,&nbsp;Yuting Ran ,&nbsp;Zheng Tang ,&nbsp;Jinrong Xu ,&nbsp;Wangen Li","doi":"10.1016/j.atherosclerosis.2025.119107","DOIUrl":"10.1016/j.atherosclerosis.2025.119107","url":null,"abstract":"<div><h3>Background and aims</h3><div>Our previous research reported a visceral fat area (VFA) estimation equation primarily based on sagittal abdominal diameter (SAD), demonstrating favorable performance compared to traditional Waist Circumference (WC)-based equations. While WC is widely used for central obesity measurement, its accuracy needs improvement. This study aims to investigate whether SAD has advantages over WC in diagnosing central obesity and to determine the optimal cut-off values for diagnosis.</div></div><div><h3>Methods</h3><div>This cross-sectional, retrospective cohort study analyzed 6762 individuals from NHANES (2011–2016) and 701 from Chinese health examinations (2023). ROC curve analysis compared AUC of different indicators in identifying two or more non-adipose components of Metabolic Syndrome (MetS).</div></div><div><h3>Results</h3><div>SAD exhibited the strongest correlation with VFA and demonstrated the strongest associations with most metabolic parameters compared to WC and BMI. Furthermore, compared with WC, SAD had significantly higher AUC values in diagnosing two or more non-adipose components of MetS, with the difference being significant in the NHANES database population (all <em>p</em> &lt; 0.001). The optimal SAD cut-off value was approximately 21.0 cm for both genders and populations, with MetS prevalence increasing rapidly at SAD≥22.0 cm. Subgroup analysis of NHANES revealed variations in optimal SAD cut-off values: Other Races (23.7 cm), Non-Hispanic Black females (18.8 cm), and other subgroups (20.0–22.0 cm).</div></div><div><h3>Conclusion</h3><div>SAD demonstrates higher efficacy than WC in diagnosing central obesity, suggesting its suitability for assessing central obesity. Additionally, SAD shows potential for a unified diagnostic cut-off value across genders and regions.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"402 ","pages":"Article 119107"},"PeriodicalIF":4.9,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143142543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular strain of the aorta and peripheral arteries in patients with type 1 diabetes mellitus in comparison with healthy controls","authors":"Markus Mueller ,&nbsp;Silvia Charwat-Resl ,&nbsp;Heike Sabine Schulze-Bauer ,&nbsp;Christina Nguyen ,&nbsp;Alexander Niessner ,&nbsp;Philipp E. Bartko ,&nbsp;Georgiana-Aura Giurgea ,&nbsp;Sonja Zehetmayer ,&nbsp;Andrea Willfort-Ehringer ,&nbsp;Alexandra Kautzky-Willer ,&nbsp;Renate Koppensteiner ,&nbsp;Oliver Schlager","doi":"10.1016/j.atherosclerosis.2025.119106","DOIUrl":"10.1016/j.atherosclerosis.2025.119106","url":null,"abstract":"<div><h3>Background and aims</h3><div>Local variations of vascular strain may be related to the development of atherosclerotic lesions. Whether vascular strain of peripheral arteries without manifest atherosclerosis is affected by diabetes mellitus is not known. This study aimed to assess vascular strain of peripheral arteries and the abdominal aorta of young patients with type 1 diabetes mellitus (T1DM) in comparison with healthy controls.</div></div><div><h3>Methods</h3><div>Vascular strain was determined by sonographic speckle tracking of the common carotid arteries (CCA), the abdominal aorta (AA), the common femoral arteries (CFA), and the popliteal arteries (PA) of patients with type 1 diabetes mellitus but without atherosclerosis and in controls.</div></div><div><h3>Results</h3><div>Thirty-three patients with T1DM (mean age 33 years, SD 11.6) and 34 controls (mean age 24 years, SD 5.4) underwent sonographic determination of vascular strain in the CCA, AA, CFA, and PA. In total 4221 clips were processed for the analysis of vascular strain. To account for a potential impact of age on vascular strain, an age-matched model containing 18 patients with T1DM and 33 controls was used for the final analysis. In this age-matched model T1DM was independently related to vascular strain in the CFA (r = −0.48; p = 0.04), while no association was observed at other sites of the vascular tree. Intima media thickness was negatively correlated with vascular strain in the AA (r = −15.11) and the PA (r = −12.76, both p &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>T1DM appears to have an early impact on vascular strain of the CFA. Longitudinal observational studies are needed to further asses the course of these changes over time and to determine the impact of these early findings on patients’ cardiovascular risk.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"402 ","pages":"Article 119106"},"PeriodicalIF":4.9,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143142542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}